Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Benjamin R. Underwood; Chris Fox

doi:10.1136/ebmed-2014-110016

Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Benjamin R. Underwood, Chris Fox

Research output: Contribution to journal › Comment/debate › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	181
Number of pages	1
Journal	BMJ Evidence-Based Medicine
Volume	19
Issue number	5
DOIs	https://doi.org/10.1136/ebmed-2014-110016
Publication status	Published - Oct 2014

Access to Document

10.1136/ebmed-2014-110016

http://ebm.bmj.com/content/19/5/181.extract

Chris Fox
- Chris.Foxuea.acuk
- Norwich Medical School - Honorary Professor
- Institute for Volunteering Research - Member
- Norwich Epidemiology Centre - Member
- Mental Health - Member
Person: Honorary, Research Group Member, Research Centre Member

Cite this

@article{c9353e5f4783498f8a56822a94b5703f,

title = "Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects",

author = "Underwood, {Benjamin R.} and Chris Fox",

note = "Commentary on: Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease. The CitAD randomised clinical trial. JAMA 2014;311:682–91.",

year = "2014",

month = oct,

doi = "10.1136/ebmed-2014-110016",

language = "English",

volume = "19",

pages = "181",

journal = "BMJ Evidence-Based Medicine",

issn = "2515-446X",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

AU - Underwood, Benjamin R.

AU - Fox, Chris

N1 - Commentary on: Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease. The CitAD randomised clinical trial. JAMA 2014;311:682–91.

PY - 2014/10

Y1 - 2014/10

U2 - 10.1136/ebmed-2014-110016

DO - 10.1136/ebmed-2014-110016

M3 - Comment/debate

VL - 19

SP - 181

JO - BMJ Evidence-Based Medicine

JF - BMJ Evidence-Based Medicine

SN - 2515-446X

IS - 5

ER -

Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects

Access to Document

Profiles

Chris Fox

Cite this